fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Merck to present new cardiovascular research at ACC.25, highlighting advances in PAH and cholesterol management

Written by | 24 Mar 2025

Merck known as MSD outside of the United States and Canada,  announced that new clinical and outcomes research data will be presented at the American College of Cardiology’s… read more.

Merck to showcase new cardiovascular research at ACC 25, including phase 3 ZENITH trial results

Written by | 21 Mar 2025

Merck known as MSD outside of the United States and Canada, announced that new clinical and outcomes research data will be presented at the American College of Cardiology’s… read more.

CHMP positive for Welireg (belzutifan) to treat von Hippel-Lindau disease and renal cell carcinoma – Merck Inc

Written by | 1 Jan 2025

Merck Inc., ( known as MSD outside of the United States and Canada), announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted… read more.

NMPA (China) approves Welireg (belzutifan), for the treatment of adult patients with von Hippel-Lindau disease – Merck Inc

Written by | 17 Dec 2024

Merck Inc. (known as MSD outside of the United States and Canada), announced that the National Medical Products Administration (NMPA) in China has approved Welireg (belzutifan), for the… read more.

Merck to showcase breakthrough data on hematologic malignancies at ASH 2024

Written by | 24 Nov 2024

Merck known as MSD outside of the United States and Canada, today announced that new data for approved and investigational medicines across multiple hematologic malignancies will be presented… read more.

Merck to Present New HIV Research and Host Symposia at the 25th International AIDS Conference in Munich

Written by | 22 Jul 2024

Merck, known as MSD outside of the United States and Canada, announced upcoming data presentations and programming at the 25th International AIDS Conference (AIDS 2024), taking place July 22-26,… read more.

FDA grants priority review to application for Keytruda + concurrent chemoradiotherapy, as treatment for newly diagnosed high-risk locally advanced cervical cancer – Merck Inc

Written by | 25 Sep 2023

Merck Inc., known as MSD outside of the United States and Canada, announced the FDA has accepted for priority review a new supplemental Biologics License Application (sBLA) seeking… read more.

Long-term follow-up data on sustained immunogenicity and safety for Gardasil 9 published in Pediatrics – Merck Inc

Written by | 12 Sep 2023

Merck Inc., known as MSD outside of the United States and Canada, announced new, 10-year long-term follow-up (LTFU) data published in the peer reviewed journal, Pediatrics, for girls… read more.

CHMP recommends Lyfnua as a treatment for refractory or unexplained chronic cough – Merck Inc

Written by | 25 Jul 2023

Merck Inc., known as MSD outside the United States and Canada, announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.